Oncolys BioPharma Inc.

4588

JP3202170001

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
706 ^JPY	-0.56%		+2.92%	+24.51%

Feb. 09	Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 07	Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	CI

Oncolys BioPharma Inc. announced that it has received ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm

July 23, 2023

On July 24, 2023, Oncolys BioPharma Inc. closed the transaction.

Latest news about Oncolys BioPharma Inc.

Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 09	CI
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	Feb. 07	CI
Oncolys Biopharma Inc. Announces the Investigator-Initiated Phase 2 Clinical Trial Agreement with Weill Cornell Medicine	Dec. 19	CI
Oncolys Biopharma Inc. Provides Update on Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Gastroesophageal Adenocarcinoma	Nov. 07	CI
Oncolys Biopharma Announces Enrollment of First Expansion Cohort Patient in Phase I Clinical Trial for Telomelysin (OBP-301)-Chemoradiation Combination Therapy	Nov. 02	CI
Oncolys BioPharma Inc. Announces Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy	23-10-16	CI
Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin?? in Combination Therapy	23-08-10	CI
Oncolys BioPharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-04	CI
Oncolys Biopharma Partner Enrolls First Patient in Phase IIa Study of Aicardi-Goutières Syndrome Drug	23-07-26	MT
Oncolys Biopharma Inc. Announces Enrollment of First Patient in Phase Iia Study for Obp-601 in Patients with Aicardi-Goutieres Syndrome	23-07-25	CI
Oncolys BioPharma Inc. announced that it has received ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	23-07-23	CI
Oncolys BioPharma Inc. announced that it expects to receive ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	23-07-06	CI
Oncolys BioPharma Announces Results from an Investigator-Initiated Phase II Clinical Trial for Telomelysin™? (OBP-301) in Combination with Pembrolizumab in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma	23-06-06	CI
Oncolys BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Amyotrophic Lateral Sclerosis	23-03-07	CI
Oncolys BioPharma Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-04	CI
Oncolys Biopharma Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	22-11-04	CI
Oncolys BioPharma Inc.(TSE:4588) dropped from S&P Global BMI Index	22-09-19	CI
Oncolys Biopharma's Drug Licensee Closes Clinical Trial Enrollment for Progressive Brain Disorder Treatment	22-08-18	MT
Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with Progressive Supranuclear Pals	22-08-17	CI
Oncolys BioPharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-05	CI
Oncolys BioPharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022	22-08-05	CI
Oncolys BioPharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022	22-05-13	CI
Oncolys BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Oncolys Biopharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022	22-02-10	CI

Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release

More about the company

	1st Jan change	Capi.
ONCOLYS BIOPHARMA INC.	+24.51%	95.81M
CSL LIMITED	-3.79%	87.06B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.25B
BIOGEN INC.	-15.94%	31.09B
UCB	+52.66%	24.74B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.91B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
INCYTE CORPORATION	-14.38%	11.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.73B

Biopharmaceuticals